11 eredmények
FIELD OF THE INVENTION
Large-scale manufacturing of a pharmaceutical composition may pose many challenges to the chemist and chemical engineer. While many of these challenges relate to the handling of large quantities of reagents and control of large-scale reactions, the handling of the final
FIELD OF THE INVENTION
The present invention is directed to pyrimidine compounds, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of prostaglandin D2
FIELD OF THE INVENTION
The present invention relates to methods for the use of chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A.sub.2 enzymes (cPLA.sub.2), more particularly including inhibitors of cytosolic phospholipase A.sub.2 alpha
FIELD OF THE INVENTION
The present invention relates to methods for the use of chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A.sub.2 enzymes (cPLA.sub.2), more particularly including inhibitors of cytosolic phospholipase A.sub.2 alpha
TECHNICAL FIELD
The present invention relates to (1) a carboxylic acid compound represented by formula (I)
##STR00002##
wherein all symbols have the same meanings as follows, salts thereof, solvates thereof, and prodrugs thereof, (2) a process for producing the same, (3) a pharmaceutical composition
TECHNICAL FIELD
The present invention relates to (1) a carboxylic acid compound represented by formula (I)
##STR00002##
wherein all symbols have the same meanings as follows, salts thereof, solvates thereof, and prodrugs thereof,
(2) a process for producing the same,
(3) a pharmaceutical composition
This invention relates to novel substituted vinyl derivatives which are capable of inhibiting thromboxane A.sub.2 (TXA.sub.2) synthetase specifically.
TXA.sub.2 is one of the arachidonic acid metabolites and is a potent inducer of platelet aggregation and vascular smooth muscle contractions.
The present invention relates to novel substituted vinylcarboxylic acid derivatives which possess the action to inhibit specifically the thromboxane A.sub.2 (TXA.sub.2) synthetase.
TXA.sub.2 is a metabolite of arachidonic acid and has the platelet aggregating action. Therefore, it has been known
TECHNICAL FIELD
The present invention relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (hereinafter referred to as "PG") I2 agonist, EP2 agonist and EP4 agonist.
BACKGROUND ART
Regeneration medical treatment is drawing
TECHNICAL FIELD
The present invention relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (hereinafter referred to as "PG") I2 agonist, EP2 agonist and EP4 agonist.
BACKGROUND ART
Regeneration medical treatment is drawing
TECHNICAL FIELD
The present invention relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (hereinafter referred to as "PG") I2 agonist, EP2 agonist and EP4 agonist.
BACKGROUND ART
Regeneration medical treatment is drawing